Clinical Trial Update: Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pemetrexed (Alimta) alone versus pemetrexed with carboplatin in advanced non-small cell lung cancer patients with performance status 2 h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Paraplatin (Carboplatin)

Snippet

Sponsor: Instituto Nacional de Cancer, Brazil | Conditions: Non Small Cell Lung Carcinoma | Phase 3 | Status: COMPLETED